Brexpiprazole Patent Expiration
Brexpiprazole is used for treating major depressive disorder (MDD) and schizophrenia in adults and pediatric patients ages 13 years and older. It was first introduced by Otsuka Pharmaceutical Co Ltd
Brexpiprazole Patents
Given below is the list of patents protecting Brexpiprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rexulti |
US10307419 (Pediatric) | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof | Apr 12, 2033 | Otsuka |
| Rexulti | US10307419 | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof | Oct 12, 2032 | Otsuka |
| Rexulti |
USRE48059 (Pediatric) | Piperazine-substituted benzothiophenes for treatment of mental disorders | Jun 23, 2029 | Otsuka |
| Rexulti | USRE48059 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Dec 23, 2028 | Otsuka |
| Rexulti |
US7888362 (Pediatric) | Piperazine-substituted benzothiophenes for treatment of mental disorders | Oct 12, 2026 | Otsuka |
| Rexulti |
US8349840 (Pediatric) | Piperazine-substituted benzothiophenes for treatment of mental disorders | Oct 12, 2026 | Otsuka |
| Rexulti |
US8618109 (Pediatric) | Piperazine-substituted benzothiophenes for treatment of mental disorders | Oct 12, 2026 | Otsuka |
| Rexulti |
US9839637 (Pediatric) | Piperazine-substituted benzothiophenes for treatment of mental disorders | Oct 12, 2026 | Otsuka |
| Rexulti | US7888362 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Apr 12, 2026 | Otsuka |
| Rexulti | US8349840 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Apr 12, 2026 | Otsuka |
| Rexulti | US8618109 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Apr 12, 2026 | Otsuka |
| Rexulti | US9839637 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Apr 12, 2026 | Otsuka |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Brexpiprazole's patents.
Latest Legal Activities on Brexpiprazole's Patents
Given below is the list recent legal activities going on the following patents of Brexpiprazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Jun, 2024 | US8349840 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Nov, 2022 | US10307419 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jun, 2021 | US8618109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 May, 2021 | US9839637 |
| Mail-Petition Decision - Granted | 08 Oct, 2020 | US7888362 |
| Petition Decision - Granted Critical
| 06 Oct, 2020 | US7888362 |
| Petition Entered | 06 Jul, 2020 | US7888362 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2020 | US8349840 |
| Mail Certificate of Correction Memo | 27 Sep, 2019 | US10307419 |
| Post Issue Communication - Certificate of Correction | 26 Sep, 2019 | US10307419 |
Brexpiprazole's Family Patents
